Martin David Harp is a journalist specializing in optometry and ophthalmology. With a focus on the national scene in Australia, Martin writes for Optometry Times and Ophthalmology Times, covering topics such as advancements in eye care, FDA approvals, innovative treatments, and the impact of COVID-19 on ophthalmology education.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Martin David Harp's coverage predominantly focuses on ophthalmology, eye care, and FDA approvals within the healthcare and pharmaceutical industry. His articles often cite data and include press releases or announcements from relevant companies or organizations in this field.
Based on his focus, Martin would likely value pitches that offer insights into groundbreaking medical advances in ophthalmology, particularly those related to new treatments, technologies, or FDA approvals. Given the emphasis on citing data and expert commentary in his coverage attributes, he may be receptive to pitches featuring credible experts who can provide insightful analysis of the latest developments in these areas.
As a journalist with a national focus on Australia but covering international topics such as COVID-19 impact on ophthalmology education in the UK, it could be beneficial to tailor pitches by highlighting any relevance or implications for the Australian context when applicable.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Martin David Harp
Most respondents were unsure of how to seek treatment and see dry eye as something that must be learned to live with.
The funding will go toward the continued clinical development of the company's lead asset, AGTC-501 (laruparetigene zovaparvovec)
By: Martin David Harp
AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill. AAV204 has been shown to achieve high macular and optic nerve transduction levels after para-retinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates.
By: Martin David Harp, Sydney M Crago
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy
Durga Borkar, MD, MMCi, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss Fas inhibition with ONL-1204 for the treatment of geographic atrophy: First-time results from a phase 1b study, which she is presenting at the ASRS meeting held in Stockholm, Sweden.
By: Martin David Harp
Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.
By: Martin David Harp
PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).
These 4 women will feature in talks across the WIO Summer Symposium. Together they welcome all attendees to the 2024 meeting in Carlsbad, California.
By: Martin David Harp
The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).
By: Hattie Hayes, Martin David Harp
Rick Lewis, MD, speaks about a non-pharmaceutical approach to treating glaucoma with laser technology
(833) 317-6278 
